Filing Flows

Filing Flows › TScan Therapeutics (TCRX) › Who owns the stock

Who owns TScan Therapeutics (TCRX) stock

60 funds reported TScan Therapeutics (TCRX) shares in their latest 13F filings, worth $37.9M in all. The largest holder is Lynx1 Capital Management LP ($7.9M). Last quarter 28 funds added to their stakes and 18 cut them.

Largest holders of TCRX (13F)Largest holders of TCRX (13F)Lynx1 Capital Management LP$7.9MBVF$5.5MBaker Bros. Advisors LP$2.7MVanguard Group$2.5MVanguard Capital Management LLC$2.1MTwo Sigma Investments, LP$1.9MRenaissance Technologies LLC$1.3MAcadian Asset Management LLC$1.3MDeer Management Co. LLC$1.2MMillennium Management LLC$1.1M

Largest holders (13F)

FundSharesValueChangeQuarter
Lynx1 Capital Management LP8,019,148$7.9Munchanged2026-06-30
BVF5,564,290$5.5Munchanged2026-06-30
Baker Bros. Advisors LP2,784,792$2.7Munchanged2026-06-30
Vanguard Group2,475,733$2.5Mincrease2025-12-31
Vanguard Capital Management LLC2,158,831$2.1Mincrease2026-06-30
Two Sigma Investments, LP1,949,604$1.9Mincrease2026-06-30
Renaissance Technologies LLC1,326,799$1.3Mdecrease2026-06-30
Acadian Asset Management LLC1,305,840$1.3Mincrease2026-06-30
Deer Management Co. LLC1,245,504$1.2Munchanged2026-06-30
Millennium Management LLC1,163,611$1.1Mdecrease2026-06-30
Jacobs Levy Equity Management1,049,806$1.0Mincrease2026-06-30
Citadel Advisors LLC1,009,107$989Kincrease2026-06-30
BlackRock994,654$975Kdecrease2026-06-30
Kalehua Capital Management LLC909,752$892Knew2026-06-30
Boothbay Fund Management, LLC772,241$757Knew2026-06-30

TScan Therapeutics' latest quarter

TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most TCRX stock?

By the latest 13F filings: Lynx1 Capital Management LP ($7.9M); BVF ($5.5M); Baker Bros. Advisors LP ($2.7M); Vanguard Group ($2.5M); Vanguard Capital Management LLC ($2.1M).

What is the short interest in TCRX?

2,277,116 shares were sold short at the 2026-10-15 settlement, -8.41% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.